Clinical jobs provider Boehringer Ingelheim has reported positive sales figures for the first half of the 2011 fiscal year.
Representing a four per cent year-on-year rise in local currency terms, the pharmaceutical company generated a net sales total of €6.4 billion (£5.6 billion).
The figures, which were in line with the organisation's internal forecasts, also revealed that prescription medicine sales were similar to that of last year.
A number of the company's speciality business units saw similar success, with double-digit increases across consumer healthcare and industrial customer divisions.
"We are pleased that Boehringer Ingelheim has further developed positively in line with our expectations, particularly also through innovative medications that are ready for the market," asserted Professor Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim.
Earlier this month, the firm revealed that its drug Pradaxa had received approval to be used to prevent strokes in patients with atrial fibrillation across Europe.